Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Current Deferred Revenue for 7 consecutive years, with $485000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Current Deferred Revenue fell 77.41% to $485000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $485000.0, a 77.41% decrease, with the full-year FY2024 number at $896000.0, down 63.08% from a year prior.
  • Current Deferred Revenue was $485000.0 for Q2 2025 at Vivos Therapeutics, down from $594000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.1 million in Q2 2021 to a low of $485000.0 in Q2 2025.
  • A 5-year average of $2.3 million and a median of $2.5 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 35.14% in 2021, then plummeted 79.73% in 2025.
  • Vivos Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then rose by 26.64% to $3.0 million in 2022, then dropped by 20.11% to $2.4 million in 2023, then plummeted by 63.08% to $896000.0 in 2024, then tumbled by 45.87% to $485000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Deferred Revenue are $485000.0 (Q2 2025), $594000.0 (Q1 2025), and $896000.0 (Q4 2024).